The European Medicines Agency’s advisory group CHMP reports that Amgen (NASDAQ:AMGN) withdrew its marketing application on May 27 for ABP 710, its biosimilar to Johnson & Johnson’s (NYSE:JNJ) Remicade (infliximab).
The agency says that the company informed it that the withdrawal was related to a change in strategy for the product.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.